applied therapeutics: Live & Latest News Updates : Vimarsana.com

APLT Stock Earnings: Applied Therapeutics Meets EPS, Misses Revenue for Q1 2024

Is Myocardial Infarction Overdiagnosed?

This Viewpoint examines whether overdiagnosis rather than underdiagnosis may now be the dominant form of myocardial infarction misdiagnosis.

Applied Therapeutics (NASDAQ:APLT) Trading Up 4.2%

New Drug Fails to Improve Diabetes-Related Heart Failure

Subanalysis finds benefit for patients not on heart-beneficial antidiabetic medication

Applied Therapeutics (NASDAQ:APLT) Shares Down 3.7%

Shares of Applied Therapeutics, Inc. (NASDAQ:APLT – Get Free Report) were down 3.7% during mid-day trading on Tuesday . The stock traded as low as $5.45 and last traded at $5.45. Approximately 133,499 shares traded hands during mid-day trading, a decline of 94% from the average daily volume of 2,099,365 shares. The stock had previously […]

Applied Therapeutics (NASDAQ:APLT) Shares Down 3.7%

Applied Therapeutics, Inc. (NASDAQ:APLT – Get Free Report)’s share price was down 3.7% during mid-day trading on Tuesday . The company traded as low as $5.45 and last traded at $5.45. Approximately 133,499 shares traded hands during trading, a decline of 94% from the average daily volume of 2,099,365 shares. The stock had previously closed […]

Applied Therapeutics (APLT) to Present Results from Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at ACC 2024

Short Interest in Applied Therapeutics, Inc. (NASDAQ:APLT) Decreases By 12.5%

Applied Therapeutics, Inc. (NASDAQ:APLT – Get Free Report) saw a large decline in short interest during the month of March. As of March 15th, there was short interest totalling 3,790,000 shares, a decline of 12.5% from the February 29th total of 4,330,000 shares. Based on an average daily volume of 2,120,000 shares, the short-interest ratio […]

Applied Therapeutics Stock (NASDAQ:APLT), Quotes and News Summary

Applied Therapeutics Stock (NASDAQ: APLT) stock price, news, charts, stock research, profile.

FDA Presses Delay Button For Applied Therapeutics' First Potential Marketed Drug For Rare Disease - Applied Therapeutics (NASDAQ:APLT)

FDA extends the review period for Applied Therapeutics' NDA for govorestat, targeting Classic Galactosemia treatment. The new action date is set for November 28, 2024. Applied Therapeutics anticipates a decision from EMA in Q4 2024.